Astria Therapeutics, Inc.

ATXS

Astria Therapeutics, Inc.

ATXS

Insider Sentiment (TTM):

Last Purchase:2024-02-01Last Sale:2024-04-01Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:51,535,959Shares Outstanding:58,005,928Institutional Ownership Pct.:88.85%

Earnings Market Reaction:

Filing Date:2025-11-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Astria Therapeutics, Inc. (ATXS) — SEC Financial Statements & Analysis

Astria Therapeutics, Inc. (ATXS) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	96	76	54	60	81	87	172	176	120	134	202	21
Short Term Investments	131	183	241	268	263	267	198	71	69	69	11	206
Accounts Receivable Net Current	17	-	-	-	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	9	9	8	7	8	3	5	4	3	1	2	1
Assets Current	254	269	303	335	352	358	375	251	191	204	215	228
Operating Lease Right Of Use Asset	4	5	5	5	5	6	0	0	1	1	1	1
Other Assets Noncurrent	14	9	3	3	4	4	4	3	2	2	2	2
Assets	272	282	310	342	362	368	379	255	194	207	218	231
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	4	4	1	2	1	2	1	1	1	1
Accrued Liabilities Current	16	16	12	13	13	13	10	10	8	5	5	8
Operating Lease Liability Current	1	1	1	1	1	1	0	0	0	1	1	1
Deferred Revenue Current	4	-	-	-	-	-	-	-	-	-	-	-
Liabilities Current	24	18	17	19	16	16	11	12	9	7	7	9
Operating Lease Liability Noncurrent	3	3	4	4	4	5	-	-	-	0	0	0
Deferred Revenue Noncurrent	12	-	-	-	-	-	-	-	-	-	-	-
Liabilities	39	21	21	23	20	21	11	12	9	7	7	9
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	911	907	902	899	895	876	873	728	638	636	635	633
Accumulated Other Comprehensive Income Loss Net Of…	0	-0	0	0	0	-0	-0	-	-	-	-0	-0
Retained Earnings Accumulated Deficit	-773	-742	-709	-675	-649	-625	-600	-581	-549	-531	-519	-508
Stockholders Equity	233	261	289	319	342	347	368	243	184	200	211	221
Liabilities And Stockholders Equity	272	282	310	342	362	368	379	255	194	207	218	231
Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Nonredeemable Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Series X Redeemable Convertible Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	56	56	56	56	56	55	55	82	84	84	84	83
Shares Outstanding	56	56	56	56	56	55	55	82	84	84	84	83

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	53.59%	48.97%	68.21%	13.08%	13.08%	89.92%	3.03%	2.71%	-	-	-	-
2024	-6.88%	-10.52%	17.31%	13.93%	21.62%	15.98%	-2.45%	-16.31%	-25.92%	-28.05%	-17.16%	-26.43%
2023	-6.28%	-31.21%	-26.18%	10.14%	-7.79%	-39.93%	20.04%	71.94%	191.76%	-1.30%	-36.89%	-36.75%
2022	-	-	-	-	-	-	-	-	-	-2.47%	10.33%	0.71%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	10.78	14.89	17.39	17.49	22.38	21.87	33.83	21.73	20.41	30.98	32.29	25.13
Quick Ratio	10.42	14.36	16.93	17.15	21.90	21.67	33.41	21.34	20.12	30.76	31.97	24.99
Working Capital	230.03M	250.54M	285.54M	315.51M	336.14M	341.52M	363.45M	239.39M	182.08M	197.82M	208.77M	218.63M
Leverage & Debt
Debt to Equity	0.17	0.08	0.07	0.07	0.06	0.06	0.03	0.05	0.05	0.03	0.03	0.04
Debt Ratio	0.14	0.08	0.07	0.07	0.06	0.06	0.03	0.05	0.05	0.03	0.03	0.04
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	8,914.58	-	-	-	-	-	-	-	-	-	-	-
Receivables Turnover TTM	0.04	-	-	-	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.14	-2.02	-1.86	-1.68	-1.73	-1.65	-1.56	-1.21	-0.98	-0.87	-0.85	-0.89
Free Cash Flow Per Share TTM	-2.07	-2.00	-1.66	-1.45	-1.63	-1.43	-1.42	-1.14	-0.87	-0.80	-0.79	-0.75
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-19,335.69%	-	-	-	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-17,567.99%	-	-	-	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	23.98%	25.40%	32.35%	29.32%	82.75%	90.22%	71.14%	40.62%	-24.49%	-28.31%	-26.15%	-76.37%
EPS Growth (1Y)	23.58%	22.12%	19.32%	38.72%	77.25%	88.74%	82.90%	36.51%	-25.98%	-33.40%	-31.20%	-85.57%
Calculated Values
Free Cash Flow TTM	-120.32M	-116.01M	-96.46M	-81.54M	-94.43M	-80.71M	-74.31M	-68.48M	-48.92M	-44.96M	-44.32M	-43.62M
Net Debt	-96.28M	-76.32M	-54.39M	-59.82M	-80.90M	-87.38M	-172.18M	-175.69M	-119.97M	-134.12M	-202.46M	-20.69M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-04-01Sale

Owner: Morabito, Christopher

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $13.59

Value: $135,900.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-02-01Purchase

Owner: Perceptive, Xontogeny Ven…

Title: -

Shares: 2,481,350

Price/Share: $12.09

Value: $29,999,521.50

Shares Owned: 4,873,721

Relationship: Director

Ownership: Indirect

2024-01-29Sale

Owner: Morabito, Christopher

Title: Chief Medical Officer

Shares: 9,200

Price/Share: $11.15

Value: $102,580.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2023-12-21Purchase

Owner: Perceptive, Advisors Llc,…

Title: -

Shares: 740,000

Price/Share: $6.20

Value: $4,588,000.00

Shares Owned: 2,392,371

Relationship: Director

Ownership: Indirect

2023-10-16Purchase

Owner: Perceptive, Life Sciences…

Title: -

Shares: 1,074,608

Price/Share: $6.51

Value: $6,995,698.08

Shares Owned: 1,652,371

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-04-01	Morabito, Christopher	Officer	Chief Medical Officer	Direct	Sale	10,000	13.59	$135,900.00	0	4
2024-02-01	Perceptive, Xontogeny Ven…	Director	-	Indirect	Purchase	2,481,350	12.09	$29,999,521.50	4,873,721	4
2024-01-29	Morabito, Christopher	Officer	Chief Medical Officer	Direct	Sale	9,200	11.15	$102,580.00	0	4
2023-12-21	Perceptive, Advisors Llc,…	Director	-	Indirect	Purchase	740,000	6.20	$4,588,000.00	2,392,371	4
2023-10-16	Perceptive, Life Sciences…	Director	-	Indirect	Purchase	1,074,608	6.51	$6,995,698.08	1,652,371	4
2022-12-19	Perceptive, Life Sciences…	Director	-	Indirect	Purchase	908,265	11.01	$9,999,997.65	1,038,309	4
2021-11-19	Komjathy, Andrew	Officer	Chief Commercial Officer	Direct	Purchase	100	6.70	$670.00	100	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

88.85%

Inst. Shares: 51,535,959

Shares Outstanding: 58,005,928

2025-09-30

96.83%

Inst. Shares: 56,166,394

Shares Outstanding: 58,005,928

2025-06-30

98.73%

Inst. Shares: 57,267,480

Shares Outstanding: 58,005,312

2025-03-31

100.15%

Inst. Shares: 58,095,074

Shares Outstanding: 58,005,312

2024-12-31

104.01%

Inst. Shares: 58,412,493

Shares Outstanding: 56,161,249

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	51,535,959	58,005,928	88.85%
2025-09-30	56,166,394	58,005,928	96.83%
2025-06-30	57,267,480	58,005,312	98.73%
2025-03-31	58,095,074	58,005,312	100.15%
2024-12-31	58,412,493	56,161,249	104.01%
2024-09-30	56,381,507	57,820,458	97.51%
2024-06-30	55,485,445	56,485,962	98.23%
2024-03-31	57,297,646	52,294,765	109.57%
2023-12-31	36,684,669	60,246,632	60.89%
2023-09-30	22,897,492	56,080,346	40.83%
2023-06-30	24,295,701	56,044,612	43.35%
2023-03-31	22,056,955	55,888,916	39.47%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Astria Therapeutics, Inc. (ATXS) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.